Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 352 of the 356 references it cites were found in a registry or an index; none of the 390 sources its claims cite is checked for support yet.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of polycystic ovary syndrome (PCOS). PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence. CONCLUSIONS: We suggest using the Rotterdam criteria for diagnosing PCOS (presence of two of the following criteria: androgen excess, ovulatory dysfunction, or polycystic ovaries). Establishing a diagnosis of PCOS is problematic in adolescents and menopausal women. Hyperandrogenism is central to the presentation in adolescents, whereas there is no consistent phenotype in postmenopausal women. Evaluation of women with PCOS should exclude alternate androgen-excess disorders and risk factors for endometrial cancer, mood disorders, obstructive sleep apnea, diabetes, and cardiovascular disease. Hormonal contraceptives are the first-line management for menstrual abnormalities and hirsutism/acne in PCOS. Clomiphene is currently the first-line therapy for infertility; metformin is beneficial for metabolic/glycemic abnormalities and for improving menstrual irregularities, but it has limited or no benefit in treating hirsutism, acne, or infertility. Hormonal contraceptives and metformin are the treatment options in adolescents with PCOS. The role of weight loss in improving PCOS status per se is uncertain, but lifestyle intervention is beneficial in overweight/obese patients for other health benefits. Thiazolidinediones have an unfavorable risk-benefit ratio overall, and statins require further study.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends using the Rotterdam criteria to diagnose PCOS in adults and emphasizes excluding mimics and assessing associated metabolic, cardiovascular, endometrial, mood, and sleep morbidity. It recommends hormonal contraceptives as first-line management for menstrual abnormalities and hirsutism/acne, clomiphene (or comparable estrogen modulators) as first-line therapy for anovulatory infertility, and metformin for T2DM/IGT or as second-line therapy for menstrual irregularity when hormonal contraceptives cannot be used.
Key findings
- PCOS diagnosis in adults should be made if two of three Rotterdam criteria are met—androgen excess, ovulatory dysfunction, or polycystic ovaries—after excluding thyroid disease, hyperprolactinemia, and nonclassic congenital adrenal hyperplasia; in adolescents, diagnosis should require clinical and/or biochemical hyperandrogenism plus persistent oligomenorrhea, because anovulatory symptoms and PCO morphology are not sufficient.
- Women with PCOS are at increased risk for impaired glucose tolerance and type 2 diabetes: the guideline states a 5- to 10-fold increased risk of developing T2DM, with overall glucose intolerance prevalence of 30–35% and T2DM in 3–10%; nonobese women with PCOS had 10–15% IGT and 1–2% T2DM.
- Hirsutism is present in approximately 65–75% of patients with PCOS, and PCOS represents the major cause of hirsutism; in a large study of patients with clinical hyperandrogenism, 72.1% of 950 patients were diagnosed with PCOS.
- Endometrial cancer risk is increased: a 31-year UK follow-up showed a 3.5 increased relative risk, and a meta-analysis reported RR = 2.7 (95% CI, 1.0–7.29), confirmed by a subsequent systematic review with a 3-fold increased risk.
- Depression and sleep-disordered breathing are also increased: one study reported major depression episode/recurrent depression OR 3.8 (95% CI, 1.5–8.7; P = .001) and suicide attempts seven times higher in PCOS cases vs controls; women with PCOS were 30 times more likely to have sleep-disordered breathing and nine times more likely to have daytime sleepiness after controlling for BMI.
Methods
- An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline using the GRADE system to describe recommendation strength and evidence quality.
- Consensus was reached through one group meeting, several conference calls, and e-mail communications; committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts.
- Two systematic reviews were conducted to summarize supporting evidence; recommendations use “we recommend” with number 1 for strong recommendations and “we suggest” with number 2 for weak recommendations, with cross-filled circles indicating evidence quality.
Limitations
- The guideline states that there are no adequately powered, randomized, double-blind, placebo-controlled trials in adolescents with PCOS; no large randomized trials of exercise in PCOS; and no long-term data assessing the effect of hormonal contraceptives on glucose tolerance in nondiabetic and diabetic women with PCOS.
- It states that there are currently no diagnostic criteria for PCOS in perimenopausal and menopausal women, no age-related testosterone cutoffs, and that testosterone assays used to diagnose hyperandrogenemia in women are imprecise.
- It notes that the Rotterdam ultrasound PCO criteria were not validated for adolescents, that there is a lack of well-defined cutoff points for androgen levels during normal pubertal maturation, and that many recommendations are weak because evidence is limited or inconclusive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 201 Not checked · 50 Own results and interpretations
In the paper
“However, hirsutism was a major symptom in about 60% of adolescents in one study (27) and may be suggestive of PCOS in adolescents (28).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 1.0 Diagnosis of PCOS
What the sources say
- Not checked yetcites [27] Pfeifer SM, Kives S Polycystic ovary syndrome in the adolescent. Obstet Gynecol Clin North Am. 2009; 36: 129– 152. 19344852
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“but our systematic review did not confirm this (211).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [211] Domecq JP, Prutsky G, Mullan R, et al Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013–2385. 24092832
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“although there were significant improvements in some metabolic parameters (mainly glycemic effects related to improvements in fasting blood glucose and insulin levels) (249, 250).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found little evidence to support lifestyle change as an infertility treatment”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Our own meta-analysis showed that weight loss had minimal effects on hirsutism and fertility”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
146 more claims
Create a free account to see all 252 claims and to verify the 390 references still open.
- It may state two separate claims as one. 78
- Probably not a substantial claim. 34
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on current guidelines, metformin is indicated in PCOS in some scenarios to improve fertility (Teede et al. , 2011; Legro et al. , 2013), for management of menstrual irregularity if women are unable to take OCPs, and in co-existent prediabetes or DM2, where lifestyle modification fails (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the interim there is inadequate evidence on the impact of metformin on glucose tolerance in prediabetes and DM2 specifically in PCOS, but based on data in general populations, current guidelines recommend using metformin in obese women with PCOS who have prediabetes or DM2 (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al. , 2013
Experimental — accuracy not yet measuredIn the citing paper
“It is indicated in combination with COCs, especially for overweight or obese patients, or when COCs are contraindicated [46].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [46]
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“implementation of evidence-based guidelines (4).”
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Self-citationThe diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 1×
“Cushing’s syndrome Many of the signs and symptoms of PCOS can overlap with Cushing’s (ie, striae, obesity, dorsocervical fat (ie, buffalo hump, glucose intolerance); however, Cushing’s is more likely to be present when a large number of signs and symptoms, especially those with high discriminatory index (eg, myopathy,…”
BackgroundThe Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 1×
“Overall, hirsutism is present in approximately 65–75% of patients with PCOS (although lower in Asian populations) (15, 52).”
BackgroundPhysical Fitness and All-Cause Mortality: A Prospective Study of Healthy Men and Women
Blair, S. N. (1989) · JAMA · doi:10.1001/jama.1989.03430170057028 · Cited by 2,658 · cited 1×
“diovascular fitness, as measured by maximal oxygen consumption during exercise, is an independent predictor of cardiovascular mortality (229).”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“Similarly, androgen levels decline with age in women with and without PCOS (serum T declines 50% between the ages of 20 and 40 y) (43–45), with reports of improved menstrual frequency in PCOS (46, 47), although there is little evidence to support a decline in serum T associated with the menopause transition per se (43…”
BackgroundSelf-citation
Research works printed but not linked: 1
- [286]Tanner JM Growth and endocrinology of the adolescent. In: Gardner LI, ed. Endocrine and Genetic Diseases of Childhood and Adolescents. 2nd ed Philadelphia, PA: WB Saunders: 1975: 14.
Cited by
Items 601–700 of 1,004
A review of metabolic and microbial influences on women with polycystic ovarian syndrome
Ravat, F. K., Goswami, J., Nair, S. M., & Thummar, K. N. (2024) · Steroids · doi:10.1016/j.steroids.2024.109512 · Cited by 28
Maan, P., Gautam, R., Vasudevan, S., Menon, G. R., Arora, A., Nair, A., Jabbar, P. K., & Arora, T. K. (2025) · Pharmaceuticals · doi:10.3390/ph18050680 · Cited by 28
“Various treatments for hirsutism and acne have been suggested, including photoepilation, topical eflornithine, anti-androgen medications, and hormonal contraceptives (Legro et al., 2013 [17]; Teede et al., 2018 [12]).”
Albaghdadi, A. J. H., & Kan, F. W. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062872 · Cited by 29
“After excluding other ovarian and endocrine disorders simulating PCOS, the diagnosis of the disease is exclusively dependent on two of three features: irregular menstrual cycles with oligo- or anovulation, and polycystic ovarian morphology (PCOM) together with clinical and/or biochemical evidence of hyperandrogenemia…”
BackgroundWaterbury, J. S., Teves, M. E., Gaynor, A., Han, A. X., Mavodza, G. R., Newell, J. M., Strauss, J. F., & McAllister, J. M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac078 · Cited by 28
Butler, A. E., Obaid, J., Wasif, P., Varghese, J. V., Abdulrahman, R., Alromaihi, D., Atkin, S. L., & Alamuddin, N. (2022) · Nutrients · doi:10.3390/nu14173491 · Cited by 28
Past and present: a bibliometric study on polycystic ovary syndrome
Cai, M., Ni, Z., Yuan, Z., Yu, J. M., Zhang, D., Yao, R., Zhou, L., & Yu, C. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01072-3 · Cited by 28
“LEGRO RS, 2013, J CLIN ENDOCR METAB [23] Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline 662”
BackgroundPossible cognition changes in women with polycystic ovary syndrome: a narrative review
Naz, M. S. G., Rahnemaei, F. A., Tehrani, F. R., Sayehmiri, F., Ghasemi, V., Banaei, M., & Ozgoli, G. (2023) · Obstetrics & Gynecology Science · doi:10.5468/ogs.22165 · Cited by 29
“Metformin and hormone therapy, including oral contraceptives, are treatment options for female with PCOS [98].”
BackgroundDepression in relation to biochemical parameters and age in women with polycystic ovary syndrome
Klimczak‐Tomaniak, D., Szlendak-Sauer, K., & Radowicki, S. (2014) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2014.10.028 · Cited by 28
Exercise in polycystic ovarian syndrome: An evidence-based review
Chandrasekaran, B., Shetty, D. R., Singh, A., & Oliverraj, J. (2017) · Saudi Journal of Sports Medicine · doi:10.4103/sjsm.sjsm_10_17 · Cited by 28
Merino, P. M., Villarroel, C., Jesam, C., López, P. V., & Ethel Codner, D. (2017) · Hormone Research in Paediatrics · doi:10.1159/000481532 · Cited by 28
Shi, Y., Kong, X., Yin, H., Zhang, W., & Wang, W. (2018) · Pathobiology · doi:10.1159/000493895 · Cited by 28
The Place of In Vitro Maturation in Assisted Reproductive Technology
Vuong, L. N., Ho, T. M., Gilchrist, R. B., & Smitz, J. E. J. (2019) · Fertility & Reproduction · doi:10.1142/s2661318219300022 · Cited by 28
Lung function changes over 8 years and testosterone markers in both sexes: UK Biobank
Lenoir, A., Fuertes, E., Real, F. G., Leynaert, B., van der Plaat, D. A., & Jarvis, D. (2020) · ERJ Open Research · doi:10.1183/23120541.00070-2020 · Cited by 28
Ospina, N. S., Rodríguez‐Gutiérrez, R., Brito, J. P., Young, W. F., & Montori, V. M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0435-z · Cited by 28
Evidence-Based Management of Infertility in Women With Polycystic Ovary Syndrome
Bergh, C., Moore, M., & Gundell, C. (2015) · Journal of Obstetric, Gynecologic & Neonatal Nursing · doi:10.1016/j.jogn.2015.10.001 · Cited by 28
“…http://jognn.org the American Diabetes Association, the Endocrine Society, and the Androgen Excess Society, recommend that all women with PCOS be screened for type 2 diabetes mellitus and impaired glucose tolerance using a 75-g 2-hr oral glucose tolerance test (Legro et al., 2013).”
BackgroundWang, Q.-Y., Song, Y., Huang, W., Xiao, L. Y., Wang, Q., & Feng, G. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.179783 · Cited by 28
Genome-wide association study for SNPs associated with PCOS in human patients
Chen, L., Hu, L., Wang, Y., Yang, H., Huang, X., Zhou, W., & Sun, H.-X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5113 · Cited by 28
Gaba, A., Hörath, S., Hager, M., Marculescu, R., & Ott, J. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05359-7 · Cited by 27
Obesity modulates cell-cell interactions during ovarian folliculogenesis
Long, X., Yang, Q., Qian, J., Yao, H., Yan, R., Cheng, X., Zhang, Q., Gu, C., Gao, F., Wang, H., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103627 · Cited by 27
Polycystic Ovary Syndrome and the Neuroendocrine Consequences of Androgen Excess
Silva, M. S. B., & Campbell, R. E. (2022) · Comprehensive physiology · doi:10.1002/cphy.c210025 · Cited by 28
Potential roles of genistein in polycystic ovary syndrome: A comprehensive systematic review
Azgomi, R. N. D., Jazani, A. M., Karimi, A., & Pourreza, S. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175275 · Cited by 27
Altuntaş, S. Ç., Celik, O., Özer, Ü., & Çolak, S. (2022) · Gynecological Endocrinology · doi:10.1080/09513590.2022.2118708 · Cited by 27
Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome
Khan, M. S., Kim, H., Kim, R., Yoon, S. H., & Kim, S. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087454 · Cited by 27
Guan, H.-R., Li, B., Zhang, Z.-H., Wu, H.-S., He, X., Dong, Y., Su, J., Lv, G., & Chen, S. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04280-6 · Cited by 27
“The drugs used to treat PCOS are mostly symptomatic interventions, such as oral contraceptives, antiandrogens, and insulin sensitizers [7].”
BackgroundMedical and surgical interventions to improve outcomes in obese women planning for pregnancy
Sharma, A. R., Bahadursingh, S., Ramsewak, S., & Teelucksingh, S. (2014) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2014.12.003 · Cited by 27
Longitudinal analyses of the steroid metabolome in obese PCOS girls with weight loss
Reinehr, T., Kulle, A. E., Rothermel, J., Knop-Schmenn, C., Lass, N., Bosse, C., & Holterhus, P. (2017) · Endocrine Connections · doi:10.1530/ec-17-0051 · Cited by 27
Karaköse, M., Hepşen, S., Çakal, E., Arslan, M. S., Tutal, E., Akın, Ş., Ünsal, İ. Ö., & Özbek, M. (2017) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.2016.0217 · Cited by 27
“(27) reported that the prevalence of autoimmune thyroiditis in PCOS was high (28, 29).”
BackgroundParaneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms
Guilmette, J. M., & Nosé, V. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.03.002 · Cited by 27
Lim, A. J. R., Indran, I. R., Kramer, M. S., & Yong, E. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.47 · Cited by 27
Mesenchymal Stem Cells in Preclinical Infertility Cytotherapy: A Retrospective Review
Chang, Z., Zhu, H., Zhou, X., Zhang, Y., Jiang, B., Li, S., Chen, L., Pan, X., & Feng, X. (2021) · Stem Cells International · doi:10.1155/2021/8882368 · Cited by 27
“According to the Rotterdam code, PCOS should be considered present when two of three criteria have been met: ovulatory dysfunction, hyperandrogenism, and/or polycystic-appearing ovarian morphology on pelvic ultrasonography [113].”
MethodMetabolic Surgery on Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
Yue, W., Huang, X., Zhang, W., Li, S., Liu, X., Zhao, Y., Shu, J., Liu, T., Li, W., & Liu, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.848947 · Cited by 27
“Currently, lifestyle management targeting weight reduction is the first-line treatment for PCOS (12).”
BackgroundSíndrome de ovario poliquístico y complicaciones metabólicas: más allá del exceso de andrógenos
García, A. F.-L., Pérez-Palacio, M. I., Molina-Valencia, J. L., & Sánchez, L. M. M. (2015) · Revista chilena de obstetricia y ginecología · doi:10.4067/s0717-75262015000600013 · Cited by 31
Clinical Implications of Polycystic Ovary Syndrome in Adolescents
Hachey, L. M., Kroger-Jarvis, M. A., Pavlik-Maus, T., & Leach, R. (2020) · Nursing for Women s Health · doi:10.1016/j.nwh.2020.01.011 · Cited by 26
Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome
Chakraborty, S., Ganie, M. A., Masoodi, I., Jana, M., Shalimar, S., Gupta, N., & Sofi, N. Y. (2020) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_610_18 · Cited by 26
Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome
Raperport, C., Chronopoulou, E., & Homburg, R. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1889366 · Cited by 26
Yin, M. X. C., Leng, L.-L., Liang, Z., Chen, X.-Y., Chan, C., & Chan, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.05.028 · Cited by 27
El-Eshmawy, M. M., Ibrahim, A. A. E. W., Bahriz, R., Shams-Eldin, N., & Mahsoub, N. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01240-y · Cited by 26
“FAI is considered to be the single most-useful test of hyperandrogenemia in women [11].”
BackgroundGlobal trends in polycystic ovary syndrome research: A 10-year bibliometric analysis
Shi, N., & Ma, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1027945 · Cited by 26
Therapeutic Potential of Mesenchymal Stem Cells in PCOS
Nejabati, H. R., Nikzad, S., & Roshangar, L. (2023) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x18666230517123256 · Cited by 27
Milutinović, D., Nikolić, M., Veličković, N., Djordjevic, A., Bursać, B., Nestorov, J., Teofilović, A., Antić, I., Macut, J., Zidane, A., et al. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-104531 · Cited by 21
Simplified 4‐item criteria for polycystic ovary syndrome: A bridge too far?
Indran, I. R., Huang, Z., Khin, L. W., Chan, J. K. Y., Viardot-Foucault, V., & Yong, E. (2018) · Clinical Endocrinology · doi:10.1111/cen.13755 · Cited by 26
Koltun, K. J., Williams, N. I., Scheid, J. L., & Souza, M. J. D. (2019) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2019-0640 · Cited by 26
“…well documented clinical characteristics of polycystic ovary syndrome (PCOS) (Rotterdam 2004a, Page 4 of 29 https://mc06.manuscriptcentral.com/apnm-pubs Applied Physiology, Nutrition, and Metabolism Draft 5 2004b), the most common endocrine disorder of women of reproductive age (Legro et al. 2013).”
BackgroundInfluentialEfficacy of Treatments for Polycystic Ovarian Syndrome Management in Adolescents
Khalifah, R. A. A., Flórez, I. D., Zoratti, M. J., Dennis, B. B., Thabane, L., & Bassilious, E. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa155 · Cited by 26
Feng, W.-Q., Zhang, Y., Pan, Y., Zhang, Y., Liu, M., Huang, Y., Xiao, Y., Mo, W., Jiao, J., Wang, X., et al. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-020-00688-8 · Cited by 27
Jobira, B., Frank, D. N., Silveira, L. J., Pyle, L. L., Kelsey, M. M., Garcia‐Reyes, Y., Robertson, C. E., Ir, D., Nadeau, K. J., & Cree‐Green, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245219 · Cited by 28
“The NIH criteria with adolescent adaptation were used to define PCOS: oligomenorrhea defined as<8 menses per year, clinical or biochemical signs of hyperandrogenism and at least 18 months post menarche [25].”
MethodDietary Total Antioxidant Capacity and Risk of Polycystic Ovary Syndrome: A Case-Control Study.
Shoaibinobarian, N., Eslamian, G., Noormohammadi, M., Malek, S., Rouhani, S., & Mirmohammadali, S. N. (2022) · PubMed Central · doi:10.22074/ijfs.2021.526579.1107 · Cited by 26
“Oxidative stress causes widespread atherosclerosis lesions in the ovarian arteries (10, 11).”
BackgroundHemostatic and Fibrinolytic Abnormalities in Polycystic Ovary Syndrome
Zoppini, G., Bonora, E., Moghetti, P., & Targher, G. (2014) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0034-1384512 · Cited by 26
Polycystic ovary syndrome: Diagnosis and management
Pfieffer, M. L. (2019) · The Nurse Practitioner · doi:10.1097/01.npr.0000553398.50729.c0 · Cited by 26
Rempert, A. N., Sarria, I., Standeven, L. R., Nylander, E., Segars, J., & Singh, B. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01285-x · Cited by 25
Cao, Z., Lu, Y., Cong, Y., Liu, Y., Li, Y., Wang, H., Zhang, Q., Huang, W., Liu, J., Dong, Y., et al. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23539 · Cited by 25
Homoeopathic treatment of women with polycystic ovarian syndrome: A prospective observational study
Gupta, G., Gupta, N., Singh, S. K., Varanasi, R., & Dewan, D. (2021) · Indian Journal of Research in Homoeopathy · doi:10.4103/ijrh.ijrh_12_20 · Cited by 25
Patil, A. D., Vaidya, R. A., Begum, S., Chauhan, S. L., Mukherjee, S., Kokate, P. P., & Joshi, B. N. (2022) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_2497_19 · Cited by 25
Kwon, S., Heo, A., & Chun, S. (2023) · Obstetrics & Gynecology Science · doi:10.5468/ogs.23103 · Cited by 25
“The TyG index was determined using the following formula: ln (fasting triglyceride [mg/dL]×fasting glucose level [mg/dL]/2) [10-19].”
BackgroundMethodCardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome
Lempesis, I. G., Apple, S. J., Duarte, G., Palaiodimos, L., Kalaitzopoulos, D. R., Dalamaga, Μ., & Kokkinidis, D. G. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3682 · Cited by 26
“management by medication or surgical interventions, insulin sensitizers, and androgen lowering agents.(3) Due to the vast array of”
BackgroundInfluentialMoghetti, P., Carmina, E., Leo, V. D., Lanzone, A., Orio, F., Pasquali, R., & Toscano, V. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0274-y · Cited by 25
“Nevertheless, other factors, including reduced oocyte competence and endometrial receptivity may be involved [9].”
BackgroundInfluentialSelf-citationTay, C. T., Joham, A. E., Hiam, D., Gadalla, M. A., Pundir, J., Thangaratinam, S., Teede, H. J., & Moran, L. (2018) · Clinical Endocrinology · doi:10.1111/cen.13753 · Cited by 25
Adolescent Polycystic Ovary Syndrome: An Update
DiVall, S. A., & Merjaneh, L. (2019) · Pediatric Annals · doi:10.3928/19382359-20190729-01 · Cited by 25
Ramos, C. D. O., Macedo, D. B., Canton, A. P. M., Cunha-Silva, M., Antonini, S. R. R., Stecchini, M. F., Seraphim, C. E., Rodrigues, T. M. B., Mendonca, B. B., Latronico, A. C., et al. (2019) · Neuroendocrinology · doi:10.1159/000504446 · Cited by 25
Kumarendran, B., O’Reilly, M., Subramanian, A., Šumilo, D., Toulis, K. A., Gokhale, K. M., Wijeratne, C. N., Coomarasamy, A., Tahrani, A. A., Azoulay, L., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0437 · Cited by 26
Is There a Relationship Between Vitamin D Deficiency Status and PCOS in Infertile Women?
Arslan, E., Görkem, Ü., & Toğrul, C. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0871-6831 · Cited by 25
“These results alone, however, are not adequate to establish a causal relationship between high measured values of anthropometric characteristics and PCOS [43].”
Javed, Z., Papageorgiou, M., Madden, L. A., Rigby, A. S., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2020) · Endocrine Connections · doi:10.1530/ec-20-0173 · Cited by 24
Oliveira, Í. M. D., Araújo, R. N., Branquinho, P. L., Neto, A. O. D. S., Lopes, C. T. D. O., & Bulla, L. L. (2024) · Journal of Social Issues and Health Sciences (JSIHS) · doi:10.5281/zenodo.13121543 · Cited by 24
Self-Administered Questionnaire to Screen for Polycystic Ovarian Syndrome
Bedrick, B. S., Eskew, A. M., Chavarro, J. E., & Jungheim, E. S. (2020) · Women s Health Reports · doi:10.1089/whr.2020.0073 · Cited by 24
“screenings, such as blood pressure, cholesterol, and hemoglobin A1C.(36) Given the significant delay in diagnosis and impact on quality of life and long-term health, identification of women at risk of PCOS is vital.”
BackgroundAn overview of polycystic ovary syndrome in aging women
Çelik, Ö., & Köse, M. F. (2021) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.galenos.2021.2021.0077 · Cited by 24
“The current recommendation is that all women with PCOS should be screened for DM at the initial visit, irrespective of age and BMI (12,23).”
BackgroundEvening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome
Barrea, L., Verde, L., Vetrani, C., Docimo, A., de Alteriis, G., Savastano, S., Colao, A., & Muscogiuri, G. (2022) · Journal of Pineal Research · doi:10.1111/jpi.12844 · Cited by 24
Assessment of Type 2 Diabetes Risk in Young Women with Polycystic Ovary Syndrome
Livadas, S., Paparodis, R. D., Anagnostis, P. G., Gambineri, A., Bjekić-Macut, J., Petrović, T., Yıldız, B. O., Micić, D., Mastorakos, G. P., & Μacut, D. (2023) · Diagnostics · doi:10.3390/diagnostics13122067 · Cited by 24
Collins, J. S. P., Beller, J. P., Solorzano, C. M. B., Patrie, J. T., Chang, R. J., Marshall, J. C., & McCartney, C. R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3258 · Cited by 24
“syndrome (PCOS) according to recent guidelines (9).”
Gao, J., Xue, J., Li, Z., Zhou, L., & Chen, C. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-016-4159-x · Cited by 24
Bitter Taste Receptor Ligand Improves Metabolic and Reproductive Functions in a Murine Model of PCOS
Wu, S., Xue, P., Grayson, N., Bland, J. S., & Wolfe, A. (2018) · Endocrinology · doi:10.1210/en.2018-00711 · Cited by 25
Lin, M.-J., Chen, H., Liu, P., Cheng, W.-J., Kuo, S.-L., & Kao, M.-C. (2019) · Medicine · doi:10.1097/md.0000000000015890 · Cited by 24
“PCOS patients whose goal is not pregnancy are usually advised to use oral contraceptives, which could correct menstrual abnormalities and hyperandrogenemia.([6,7]) However, treatment with oral contraceptives would increase the risk of venous thromboembolism.”
BackgroundRs1799817 in INSR associates with susceptibility to polycystic ovary syndrome
Daghestani, M. H. (2019) · Journal of Medical Biochemistry · doi:10.2478/jomb-2019-0023 · Cited by 25
Polycystic ovary syndrome (PCOS) and adolescence: How can we manage it?
Capozzi, A., Scambia, G., & Lello, S. (2020) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2020.04.024 · Cited by 25
Diri, H., Karaburgu, S., Açmaz, B., Ünlühızarcı, K., Tanrıverdi, F., Karaca, Z., & Keleştimur, F. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1080679 · Cited by 24
“hirsutism, androgenic alopecia, and acne in PCOS was limited and very inferior to anti-androgen drugs [1,29], numerous studies showed that metformin has significant effects on those features of”
Background(2014) · doi:10.1007/978-1-4471-2789-5_13 · Cited by 23
Zhuang, J., Wang, Y., Wang, S., Hu, R., & Wu, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-64849-0 · Cited by 23
“% for Categorical variables: p value was calculated by the weighted chi-square test. www.nature.com/scientificreports/ of infertility in obese women by three times compared to non-obese women 34 .”
Shekarian, A., Mazaheri‐Tehrani, S., Shekarian, S., Pourbazargan, M., Setudeh, M., Abhari, A. P., Fakhrolmobasheri, M., & Heidarpour, M. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01896-2 · Cited by 23
“It is also used as adjuvant therapy with letrozole and clomiphene citrate for ovulation induction [4, 80, 81].”
Balogh, Z., Csehely, S., Orosz, M., Bhattoa, H. P., Krasznai, Z. T., Deli, T., & Jakab, A. (2025) · Biomedicines · doi:10.3390/biomedicines13081803 · Cited by 23
“Beyond these reproductive manifestations, PCOS is also strongly associated with metabolic complications such as insulin resistance, dyslipidemia, and obesity, which increase the long-term risk of type 2 diabetes mellitus and cardiovascular disease [3,4].”
Chen, X., Wan, Y., & Xie, L. (2025) · Biology of Reproduction · doi:10.1093/biolre/ioaf197 · Cited by 23
Morris, S., Grover, S. R., & Sabin, M. A. (2015) · Clinical Obesity · doi:10.1111/cob.12123 · Cited by 24
“In the interim, current guidelines recommend clinicians rely on mass spectrometry assays (if available), as well as familiarity with local assays to guide interpretation of results (7).”
BackgroundMethodInfluentialA Review on Medicinal Plants of Natural Origin for Treatment of Polycystic Ovarian Syndrome (PCOS)
Andhalkar, S., Chaware, V. J., & Redasani, V. (2021) · Asian Journal of Pharmaceutical Research and Development · doi:10.22270/ajprd.v9i3.949 · Cited by 23
Begum, R. F., & Mohan, S. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04710-8 · Cited by 23
“High insulin levels also elevate testosterone synthesis and lower sex hormone-binding globulin (SHBG) [37].”
Palomba, S., Costanzi, F., Caserta, D., & Vitagliano, A. (2024) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2024.104381 · Cited by 24
Leukocyte dynamics in female reproductive health: roles and mechanisms
Obeagu, E. I., & Obeagu, G. U. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002926 · Cited by 23
Mehrabian, F., Tehrani, H. G., Mohamadkhani, M., Moinoddini, M., & Karimzadeh, P. (2016) · Journal of Research in Medical Sciences · doi:10.4103/1735-1995.177354 · Cited by 23
(2018) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1490405 · Cited by 22
“…production by stimulating ovarian steroido-genesis through the following: (1) insulin binds to the insulin-like growth factor (IGF) receptors [2,3,5], and transmits its signals to the ovary, which is already in a hyperandrogenic state because of an enzymatic dysregulation of cytochrome…”
BackgroundRetractedKumar, K. S. H., Kumar, Y., Kotwal, N., Singh, Y., Upreti, V., & Somani, S. (2018) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_83_17 · Cited by 23
“Few studies have shown that patients using metformin have lost weight whereas those using OCP have gained weight.[22] However, our data did not show any such discrepant observation.”
BackgroundKiller-cell immunoglobulin-like receptors associated with polycystic ovary syndrome
Elpídio, L. N. S., de Alencar, J. B., Tsuneto, P. Y., Alves, H. V., Toretta, M. T., Taura, S. K. I., Visentainer, J. E. L., & Sell, A. M. (2018) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2018.08.003 · Cited by 23
Antiproliferative and ameliorative effects of Tetracera potatoria and its constituent
Ogunlakin, A. D., Sonibare, M. A., Jabeen, A., Shaheen, F., & Shah, S. F. (2020) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-020-00511-0 · Cited by 23
Lin, A., Siscovick, D. S., Sternfeld, B., Schreiner, P. J., Lewis, C. E., Wang, E. T., Merkin, S. S., Wellons, M., Steffen, L. M., Calderon‐Margalit, R., et al. (2021) · BMC Public Health · doi:10.1186/s12889-020-10028-5 · Cited by 23
Brown Adipose Transplantation Improves Polycystic Ovary Syndrome-Involved Metabolome Remodeling
Yao, L., Wang, Q., Zhang, R., Wang, X., Liu, Y., Di, F., Song, L., & Xu, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.747944 · Cited by 23
Polycystic Ovary Syndrome: Insights from Preclinical Research
Reckelhoff, J. F., Shawky, N. M., Romero, D. G., & Cardozo, L. L. Y. (2022) · Kidney360 · doi:10.34067/kid.0002052022 · Cited by 23
Herman, T., Csehely, S., Orosz, M., Bhattoa, H. P., Deli, T., Török, P., Laganà, A. S., Chiàntera, V., & Jakab, A. (2022) · Reproductive Sciences · doi:10.1007/s43032-022-01137-0 · Cited by 23
Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes
Ortiz-Flores, A. E., Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528231 · Cited by 23
“75 g OGTT is the most appropriate diagnostic tool for the assessment of glucose tolerance in women with PCOS [1,40,41].”
BackgroundMethodOrio, F., Muscogiuri, G., & Palomba, S. (2015) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2015.53 · Cited by 23
Aldosterone in gynecology and its involvement on the risk of hypertension in pregnancy
Sabbadin, C., Andrisani, A., Ambrosini, G., Bordin, L., Donà, G., Manso, J., Ceccato, F., Scaroni, C., & Armanini, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00575 · Cited by 22
Metabolic effects of polycystic ovary syndrome in adolescents
Han, Y., Kim, H. S., Lee, H.-J., Oh, J.-Y., & Sung, Y.-A. (2015) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2015.20.3.136 · Cited by 22
Xu, X., Hu, K., Shi, H., Yu, Y., Xu, J., & Sun, Y. (2021) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2021.06.012 · Cited by 22
Large animal models in the study of gynecological diseases
Cui, M., Liu, Y., Men, X., Li, T., Liu, D., & Deng, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1110551 · Cited by 22
“Hyperandrogenemia leads to abnormal follicular development, obesity, and hirsutism, which cause greater distress for women (Legro et al., 2013; Azziz et al., 2016; Lizneva et al., 2016; Rosenfield and Ehrmann, 2016; Zeng et al., 2020).”
BackgroundDeterminants and Assessment of Menstrual Blood Flow
Liang, J., Ali, F., Ramaiyer, M. S., & Borahay, M. A. (2023) · Current Epidemiology Reports · doi:10.1007/s40471-023-00332-0 · Cited by 23
“PCOS in individuals with a BMI >= 25 [67] may be treated with calorie-restricted diets [68, 69] because even a small weight loss, 5–10%, can improve menstrual irregularities [68].”
BackgroundSkowrońska, M., Pawłowski, M., & Milewski, R. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196275 · Cited by 22
“The Rotterdam Criteria is the most widely used classification of PCOS, now endorsed by most scientific societies and health authorities [15–18].”
Method
Metadata
- Authors
- Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K.
- Affiliations
- Pennsylvania State University (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-12
- Volume
- 98
- Issue
- 12
- Pages
- 4565-4592
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC5399492
- OpenAlex
- W2120973019
- Cited by
- 1,919
- References
- 356
- Citations by year
- 2026: 104 · 2025: 135 · 2024: 149 · 2023: 181 · 2022: 207 · 2021: 197 · 2020: 149 · 2019: 160 · 2018: 145 · 2017: 129 · 2016: 131 · 2015: 124 · 2014: 95 · 2013: 6
- FWCI
- 143.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institute of Diabetes and Digestive and Kidney Diseases (P60DK020595, P30DK020595)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD065029)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, PCOS diagnosis, Rotterdam criteria, hyperandrogenism, ovulatory dysfunction, PCOS treatment, hormonal contraception, clomiphene citrate, metformin, insulin resistance, menstrual irregularity, hirsutism, acne, infertility, adolescents, menopausal women, weight loss, lifestyle intervention, thiazolidinediones, statins, cardiovascular risk
- MeSH terms
- Adolescent, Adult, Age Factors, Female, Humans, Middle Aged, Polycystic Ovary Syndrome, Societies, Scientific, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.